Senores Pharmaceuticals Limited has informed the Exchange about Submission of Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2026 under Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals submitted its quarterly share capital audit report certified by practicing Company Secretary Tapan Shah. The company has an issued and listed equity capital of 4,60,53,588 shares with face value of Rs. 10 each. All shares are fully dematerialized (63.32% in NSDL, 36.68% in CDSL, 0% in physical form), indicating strong compliance. The audit also noted three material corporate actions: (1) Preferential allotment of 11,70,000 convertible equity warrants to promoters on March 28, 2026, (2) resignation of Mr. Manohar Lalge as President-R&D effective March 17, 2026, and (3) appointment of Mr. Jatin Gajjar as Senior Management Personnel effective March 17, 2026.
The 100% dematerialization is positive for shareholder safety. However, the preferential warrant issuance to promoters dilutes the equity base, which existing shareholders should note. The R&D head's resignation warrants monitoring for potential impact on operations.